April 3, 2017 09:47 AM EDTUpdated 10:14 AM

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta

Shehla Shakoor

Managing Director

→ Roche reported this morning that its latest Phase III study for Alecensa (alectinib) came through, hitting the endpoint on progression-free survival for non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Roche scores a suc­cess for Ale­cen­sa PhI­II; FDA sched­ules Ad­Comm for Hep­lisav-B; New CMO at Sarep­ta

Managing Director

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta